Outpatient treatment of narcotics addicts with agents that block the appealing euphoria of drugs is showing early promise in several New York City studies.
Short-term results using cyclazocine or methadone in therapy were discussed at two recent meetings— the Fifth International Congress of the Collegium Internationale Neuro-Psychopharmacologicum in Washington, DC, and the Illinois State Medical Society's Conference on Narcotic Addiction, held in Chicago.
Addict treatment on an outpatient basis, rather than under extended confinement, is the common goal of pilot programs with both agents.
All current studies involve comparatively small groups and still are well within the lengthy followup period necessary in narcotics studies. "This is all a very new approach," cautioned William R. Martin, MD. "Only time will tell whether these are better agents than the many already tried for maintenance therapy."
Cyclazocine, a narcotic antagonist structurally similar to nalorphine, was first tested on addicts at the National Institute